Correct Answer: D

Rationale:
Choice D is correct because opioids (e.g., oxycodone), benzodiazepines (e.g., alprazolam), and stimulants (e.g., Adderall) are frequently misused for euphoria or dependence, per DEA data.
Choice A is incorrect alone as it's one class.
Choice B is wrong by itself because benzos are just part.
Choice C is incorrect solo since stimulants are only one group.

Correct Answer: D

Rationale:
Choice D is correct because enteric-coated tablets (altered absorption), extended-release formulations (disrupted timing), and capsules (uneven dosing) shouldn't be split, risking efficacy or toxicity.
Choice A is incorrect alone as it's one type.
Choice B is wrong by itself because extended-release is just part.
Choice C is incorrect solo since capsules are only one category.

Correct Answer: B

Rationale:
Choice B is correct because hypothalamic-pituitary-adrenal suppression from chronic prednisone is a type C ADR, linked to long-term use causing cumulative effects on endocrine function.
Choice A is incorrect as type B is idiosyncratic, not chronic.
Choice C (type E) is wrong because type E involves withdrawal effects, not ongoing suppression.
Choice D (type F) is incorrect as type F is dose reduction failure, not applicable here.

Correct Answer: B

Rationale:
Choice B is correct because men's higher lean mass increases the volume of distribution for water-soluble drugs, reducing concentrations and effectiveness.
Choice A is incorrect as lipid-soluble drugs benefit from fat, not lean mass.
Choice C is wrong because protein binding isn't lean-mass dependent.
Choice D is incorrect since only water-soluble drugs fit.

Correct Answer: A

Rationale:
Choice A is correct because Schedule II drugs (e.g., oxycodone) require a written prescription without refills, per DEA rules.
Choice B is incorrect as refills are allowed for Schedule III-V, not a requirement.
Choice C is wrong because e-prescribing is permitted with security.
Choice D is incorrect since only A is a mandate.